PHVS – pharvaris n.v. - ordinary shares (US:NASDAQ)

News

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference [Yahoo! Finance]
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Pharvaris (PHVS) had its "buy" rating reaffirmed by Citigroup Inc..
Pharvaris (PHVS) was downgraded by Wall Street Zen from "sell" to "st
Pharvaris (PHVS) was upgraded by Wolfe Research to "strong-buy".
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com